Akeso Inc

Akeso Inc., incorporated in 2012 and headquartered in Zhongshan, Guangdong, China, is a prominent player in the biopharmaceutical sector. Specializing in research and development, the company is dedicated to creating, manufacturing, and marketing new therapies aimed at treating diseases like cancer and autoimmune disorders. A leading product of Akeso Inc. is Cadonilimab, an innovative bispecific antibody referred to as AK104, which showcases the company's commitment to advancing medical treatments. With its principal market being China, Akeso focuses on serving the Chinese healthcare space through its research, development, and commercial efforts. While the company may enter collaborations to broaden its international presence, the significance of markets outside China hinges on the prevailing business strategies and particular medications or services under consideration. (Powered by AI)